Study to Evaluate the Safety and Efficacy of 13 Weeks of the Selective Androgen Receptor Modulator (SARM) GSK2881078 in Chronic Obstructive Pulmonary Disease (COPD)

NCT03359473 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

97

Enrollment

INDUSTRY

Sponsor class

Conditions

Cachexia

Interventions

DRUG: GSK2881078
DRUG: Matching Placebo

Sponsor

GlaxoSmithKline

Collaborators

[object Object]